ANGELA KULESZA: Open Payments
NPI 1235107210 · TEWKSBURY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,080 in 114 payments from 25 companies in 2025. Trend: 2023 $2,338 · 2024 $2,023 · 2025 $3,080
Food & beverage: $3,080
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $436 |
| AstraZeneca Pharmaceuticals LP | 11 | $424 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $310 |
| E.R. Squibb & Sons, L.L.C. | 10 | $257 |
| Alnylam Pharmaceuticals Inc. | 2 | $250 |
| Abbott Laboratories | 9 | $167 |
| Otsuka America Pharmaceutical, Inc. | 9 | $161 |
| HEARTFLOW, INC. | 2 | $160 |
| Lundbeck LLC | 6 | $150 |
| PFIZER INC. | 9 | $147 |
Products named: REXULTI, Kerendia, VRAYLAR, AMVUTTRA, ELIQUIS, BREZTRI, AIRSUPRA, FREESTYLE LIBRE 3.
Industry payments across MA — which companies pay providers there.
